Head-to-head · free
Doximity, Inc. vs Genmab
DOCS vs GMAB — return on capital, cash generation, margins and balance sheet side by side.
DOCS
3 / 5
measures where DOCS leads
GMAB
2 / 5
measures where GMAB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | DOCS · FY2026 | GMAB |
|---|---|---|
| Revenue | $644.9M | — |
| Net income | $196.1M | — |
| Revenue growth (yearly, multi-year) | 17.0% | — |
| Free cash flow | $326.5M | — |
| Free cash flow margin | 50.6% | — |
| Net cash / (debt) | — | — |
| ROIC | 16.4% | 10.1% |
| Return on equity | 19.3% | 17.5% |
| Gross margin | 89.1% | 93.6% |
| Operating margin | 33.3% | 33.6% |
| Net debt / EBITDA | -0.96x | 3.13x |
Figures are as reported by each company; latest fiscal year shown.
Where Doximity, Inc.'s cash went (FY2026)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free